newsfilter
← Latest News
GlobeNewswire·

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates

- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic